8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Feb 27, 2026·SEC
MBX Biosciences, Inc. Common Stock(MBX)Earnings, Financials & Key Ratios
MBX•NASDAQ
$32.12
$1.44B mkt cap·Price updated May 6, 2026
AboutMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Show more
- Revenue$0
- EBITDA-$68M-93.3%
- Net Income-$62M-90.2%
- EPS (Diluted)-1.85-81.4%
- ROE-66.95%
- ROIC-96.87%
- Debt/Equity0.00
MBX Key Insights
MBX Biosciences, Inc. Common Stock (MBX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 84 (top 16%)
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MBX Price & Volume
MBX Biosciences, Inc. Common Stock (MBX) stock price & volume — 10-year historical chart
Loading chart...
MBX Growth Metrics
MBX Biosciences, Inc. Common Stock (MBX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-43.11%
Return on Capital
10 Years-52.9%
5 Years-52.9%
3 Years-52.9%
Last Year-40.38%
MBX Recent Earnings
MBX Biosciences, Inc. Common Stock (MBX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/9 qtrs (83%)
Q2 2026Latest
Mar 12, 2026EPS
$0.49
Est $0.64
+23.4%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.63
Est $0.73
+13.7%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.58
Est $0.77
+24.7%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.71
Est $0.81
+12.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.49vs $0.64+23.4% | — |
| Q4 2025 | Nov 6, 2025 | $0.63vs $0.73+13.7% | — |
| Q3 2025 | Aug 7, 2025 | $0.58vs $0.77+24.7% | — |
| Q2 2025 | May 12, 2025 | $0.71vs $0.81+12.3% | — |
Based on last 9 quarters of dataView full earnings history →
MBX Peer Comparison
MBX Biosciences, Inc. Common Stock (MBX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CGEM | 903.06M | 14.99 | -4.03 | -46.19% | 0.01 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PEPG | 127.07M | 1.85 | -0.87 | -75.73% | 0.12 | |||
 CYCN | 14.03M | 3.24 | -2.97 | 3.7% | -170.11% | -39.23% | ||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare MBX vs Peers
MBX Biosciences, Inc. Common Stock (MBX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MBX Income Statement
MBX Biosciences, Inc. Common Stock (MBX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 90.87M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 16.25M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 21.4M | 28.53M | 57.41M | 74.62M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -25.16M▲ 0% | -35.31M▼ 40.3% | -68.19M▼ 93.1% | -90.87M▲ 0% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -40.34% | -93.12% | - |
| EBITDA | -25.11M | -35.15M | -67.95M | -90.62M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -40.03% | -93.29% | -52.7% |
| D&A (Non-Cash Add-back) | 56K | 157K | 244K | 246K |
| EBIT | -25.76M | -35.31M | -68.19M | -88.56M |
| Net Interest Income | -2K | 2.75M | 6.27M | 8.07M |
| Interest Income | 372K | 2.75M | 6.27M | 8.07M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income/Expense | -974K | 2.75M | 6.27M | 10.38M |
| Pretax Income | -26.14M▲ 0% | -32.56M▼ 24.6% | -61.92M▼ 90.2% | -80.5M▲ 0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -26.14M▲ 0% | -32.56M▼ 24.6% | -61.92M▼ 90.2% | -80.5M▲ 0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -24.6% | -90.16% | -45.88% |
| Net Income (Continuing) | -26.14M | -32.56M | -61.92M | -80.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.82▲ 0% | -1.02▼ 24.4% | -1.85▼ 81.4% | -2.35▲ 0% |
| EPS Growth % | - | -24.39% | -81.37% | -43.11% |
| EPS (Basic) | -0.82 | -1.02 | -1.85 | - |
| Diluted Shares Outstanding | 31.85M | 31.85M | 33.39M | 34.2M |
| Basic Shares Outstanding | 31.85M | 31.85M | 33.39M | 34.2M |
| Dividend Payout Ratio | - | - | - | - |
MBX Balance Sheet
MBX Biosciences, Inc. Common Stock (MBX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 44.21M | 83.47M | 267.29M | 397.5M |
| Cash & Short-Term Investments | 42.46M | 80.68M | 262.15M | 391.67M |
| Cash Only | 24.21M | 30.52M | 49.35M | 223.13M |
| Short-Term Investments | 18.25M | 50.15M | 212.8M | 168.55M |
| Accounts Receivable | 142K | 208K | 682K | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 84K | 133K | 803K | 2.43M |
| Total Non-Current Assets | 884K | 715K | 1.25M | 2.57M |
| Property, Plant & Equipment | 842K | 665K | 1.2M | 2.52M |
| Fixed Asset Turnover | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 42K | 50K | 50K | 200K |
| Total Assets | 45.09M▲ 0% | 84.18M▲ 86.7% | 268.54M▲ 219.0% | 400.08M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 86.67% | 219% | 755.36% |
| Total Current Liabilities | 3.43M | 3.93M | 11.05M | 12.06M |
| Accounts Payable | 976K | 1.39M | 5.33M | 3.77M |
| Days Payables Outstanding | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.13M | 1.36M | 2.32M | 0 |
| Current Ratio | 12.89x | 21.26x | 24.19x | 24.19x |
| Quick Ratio | 12.89x | 21.26x | 24.19x | 24.19x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 84.27M | 152.72M | 42K | 476K |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 324K | 171K | 0 | 981K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 83.94M | 152.55M | 42K | 87K |
| Total Liabilities | 87.7M | 156.65M | 11.09M | 12.54M |
| Total Debt | 461K | 324K | 171K | 623K |
| Net Debt | -23.75M | -30.2M | -49.18M | -222.5M |
| Debt / Equity | - | - | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | 2.46x |
| Interest Coverage | -67.28x | - | - | - |
| Total Equity | -42.6M▲ 0% | -72.47M▼ 70.1% | 257.44M▲ 455.2% | 387.54M▲ 0% |
| Equity Growth % | - | -70.09% | 455.25% | 1061.7% |
| Book Value per Share | -1.34 | -2.28 | 7.71 | 11.33 |
| Total Shareholders' Equity | -42.6M | -72.47M | 257.44M | 387.54M |
| Common Stock | 1K | 1K | 5K | 6K |
| Retained Earnings | -43.02M | -75.58M | -137.5M | -202.41M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3K | 60K | 55K | 154K |
| Minority Interest | 0 | 0 | 0 | 0 |
MBX Cash Flow Statement
MBX Biosciences, Inc. Common Stock (MBX) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -23.12M | -31.98M | -54.68M | -54.68M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -38.3% | -71% | -233.87% |
| Net Income | -26.14M | -32.56M | -61.92M | -80.5M |
| Depreciation & Amortization | 56K | 157K | 244K | -794K |
| Stock-Based Compensation | 306K | 2.04M | 5.22M | 7.51M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.36M | -880K | -2.82M | -5.33M |
| Working Capital Changes | 1.29M | -735K | 4.6M | 1.42M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 671K | 412K | 3.93M | 1.09M |
| Cash from Investing | -11.41M | -30.93M | -160.59M | -21.08M |
| Capital Expenditures | -441K | -129K | -874K | -1.23M |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 23.45M |
| Cash from Financing | 46.06M | 69.22M | 234.1M | 189.02M |
| Debt Issued (Net) | 10M | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | -428K | 709K | -3.94M | 187.69M |
| Net Change in Cash | 11.53M▲ 0% | 6.31M▼ 45.2% | 18.83M▲ 198.2% | 90.26M▲ 0% |
| Free Cash Flow | -23.56M▲ 0% | -32.11M▼ 36.3% | -55.55M▼ 73.0% | -78.91M▲ 0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -36.26% | -73.03% | -55.87% |
| FCF per Share | -0.74 | -1.01 | -1.66 | -1.66 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.98x | 0.88x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
MBX Key Ratios
MBX Biosciences, Inc. Common Stock (MBX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | - | -66.95% | -20.77% |
| Return on Invested Capital (ROIC) | - | -96.87% | -96.87% |
| Debt / Equity | - | 0.00x | 0.00x |
| FCF Conversion | 0.98x | 0.88x | 0.98x |
MBX SEC Filings & Documents
MBX Biosciences, Inc. Common Stock (MBX) SEC filings — annual & quarterly reports (10-K, 10-Q)
MBX Frequently Asked Questions
MBX Biosciences, Inc. Common Stock (MBX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MBX Biosciences, Inc. Common Stock (MBX) grew revenue by 0.0% over the past year. Growth has been modest.
MBX Biosciences, Inc. Common Stock (MBX) reported a net loss of $80.5M for fiscal year 2024.
Dividend & Returns
MBX Biosciences, Inc. Common Stock (MBX) has a return on equity (ROE) of -67.0%. Negative ROE indicates the company is unprofitable.
MBX Biosciences, Inc. Common Stock (MBX) had negative free cash flow of $78.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More MBX
MBX Biosciences, Inc. Common Stock (MBX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates